Imexpharm

HOSE-IMP
Ho Chi Minh Stock Exchange NYSE
Pharmaceutical Preparations
Global Rank
#17233
Country Rank
n/a
Market Cap
305.49 M
Price
1.98
Change (%)
0.58%
Volume
213,534

HOSE-IMP's Next Dividend

Next Estimated Amount
₫350
Next Estimated Pay Date
04/26/2025
Last Amount
₫500
Last Pay Date
07/23/2024
Dividend Shot Clock Ex-Date: 07/11/2024
0
Days
0
Hours
0
Minutes
0
Seconds
Ex-dividend date passed

Imexpharm Dividend Chart

*Amounts are shown in the stock exchange currency (VND) for convenience

Imexpharm(HOSE-IMP) Dividend History

Imexpharm (HOSE-IMP) currently pays an annual dividend of $500.00 per share, offering a dividend yield of 0.96%. The next dividend payout date has not been announced.
Ex-Dividend Date Adj. Amount Record Date Pay Date Change (%)
2024 ₫500 10%
07/11/2024 ₫500 07/12/2024 07/23/2024 10%
2023 ₫454.54 -30%
10/05/2023 ₫454.54 10/06/2023 10/20/2023 -30%
2022 ₫649.35 0%
05/25/2022 ₫649.35 05/26/2022 06/24/2022 0%
2021 ₫649.35 50%
06/23/2021 ₫649.35 06/24/2021 07/16/2021 50%
2020 ₫432.9
07/14/2020 ₫432.9 07/15/2020 07/31/2020
*Amounts are shown in the stock exchange currency (VND) for convenience
*Historical information is adjusted for stock splits

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking
Community

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.